Drug Profile
Thymalfasin - SciClone Pharmaceuticals
Alternative Names: Thymosin-α-1; Tα 1; ZadaxinLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator University of Texas at Austin
- Developer SciClone Pharmaceuticals; sigma-tau SpA
- Class Adjuvants; Anti-infectives; Antineoplastics; Antivirals; Oligopeptides; Thymus hormones
- Mechanism of Action Th1 cell stimulants; Th2 cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Malignant melanoma
Highest Development Phases
- Marketed Cancer; Hepatitis B; Hepatitis C
- Phase III Sepsis
- Clinical Phase Unknown COVID 2019 infections
- Discontinued Liver cancer; Malignant melanoma; Non-small cell lung cancer
Most Recent Events
- 26 Apr 2021 Clinical trials in COVID-2019 infections (Combination therapy) in China (Parenteral)
- 08 Apr 2021 Discontinued - Phase-II for Liver cancer in USA (Intrahepatic)
- 08 Apr 2021 Discontinued - Phase-II for Malignant melanoma in Europe (Parenteral)